CN Patent

CN103044391B — 一种高效的dpp-iv抑制剂

Assigned to Guangzhou Institute of Biomedicine and Health of CAS · Expires 2015-11-25 · 10y expired

What this patent protects

本发明属于医药技术领域，涉及一种高效的DPP-IV抑制剂，具体地涉及一种以脲嘧啶为母核的化合物或其盐、其制备方法、组合物以及这类化合物作为二肽基肽酶(DPP-IV)抑制剂在预防或治疗受益于DPP-IV抑制的疾病中的用途。本发明化合物对DPP-IV具有非常好的选择性抑制作用，心脏毒性也非常低，是非常有前景的DPP-IV抑制剂类药物。

USPTO Abstract

本发明属于医药技术领域，涉及一种高效的DPP-IV抑制剂，具体地涉及一种以脲嘧啶为母核的化合物或其盐、其制备方法、组合物以及这类化合物作为二肽基肽酶(DPP-IV)抑制剂在预防或治疗受益于DPP-IV抑制的疾病中的用途。本发明化合物对DPP-IV具有非常好的选择性抑制作用，心脏毒性也非常低，是非常有前景的DPP-IV抑制剂类药物。

Drugs covered by this patent

Patent Metadata

Patent number: CN103044391B
Jurisdiction: CN
Classification: —
Expires: 2015-11-25
Drug substance claim: No
Drug product claim: No
Assignee: Guangzhou Institute of Biomedicine and Health of CAS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.